NDC 49401-103

Raxibacumab

Raxibacumab

Raxibacumab is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by Human Genome Sciences, Inc.. The primary component is Raxibacumab.

• Product ID: 49401-103_7ca23f5f-4c47-4280-a2e8-433b69e1f5cc
• NDC: 49401-103
• Product Type: Human Prescription Drug
• Proprietary Name: Raxibacumab
• Generic Name: Raxibacumab
• Dosage Form: Injection
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2012-12-14
• Marketing End Date: 2022-05-31
• Marketing Category: BLA / BLA
• Application Number: BLA125349
• Labeler Name: Human Genome Sciences, Inc.
• Substance Name: RAXIBACUMAB
• Active Ingredient Strength: 50 mg/mL
• Pharm Classes: Anthrax Protective Antigen-directed Antibody [EPC],Anthrax Protective Antigen-directed Antibody Interactions [MoA]
• NDC Exclude Flag: N

Packaging

NDC 49401-103-01

1 VIAL, SINGLE-USE in 1 CARTON (49401-103-01) > 34 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2012-12-14
• Marketing End Date: 2022-05-31
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 49401-103-01 [49401010301]

Raxibacumab INJECTION

• Marketing Category: BLA
• Application Number: BLA125349
• Product Type: HUMAN PRESCRIPTION DRUG
• Marketing Start Date: 2012-12-14
• Marketing End Date: 2022-05-31

Drug Details

Active Ingredients

Ingredient	Strength
RAXIBACUMAB	50 mg/mL

OpenFDA Data

• SPL SET ID: a79c6f44-e978-44c3-b843-69793b03e830
• Manufacturer:
  • Human Genome Sciences, Inc.
• UNII:
  • 794PGL549S
• RxNorm Concept Unique ID - RxCUI:
  • 1366571

Pharmacological Class

• Anthrax Protective Antigen-directed Antibody [EPC]
• Anthrax Protective Antigen-directed Antibody Interactions [MoA]
• Anthrax Protective Antigen-directed Antibody [EPC]
• Anthrax Protective Antigen-directed Antibody Interactions [MoA]

NDC Crossover Matching brand name "Raxibacumab" or generic name "Raxibacumab"

NDC	Brand Name	Generic Name
49401-103	Raxibacumab	raxibacumab
71655-103	Raxibacumab	raxibacumab